Caution required for biosimilars

While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug antibodies caused by the use of biosimilars, warns Dr Greg Moore, Head of IBD at Monash Medical Centre in Melbourne and a Senior Lecturer in

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous World news wrapup: 6 October 2016
Next Forum: why havent I reached the safety net yet?